Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The appointment puts the Sage and Voyager co-founder in charge of advancing a muscarinic agonist he worked on at Eli Lilly in the 1990s.
Pharma veteran Geno Germano is taking the CEO spot at Elucida Oncology, which is developing a nanoparticle platform to diagnose and treat cancer.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Cheng’s exit keeps the revolving door spinning at Gilead, which is set to lose its CEO, CMO, CSO and executive chairman over a nine-month window.
New insights into how the tumor-suppressing gene p53 protects elephants from cancer could be used to develop new drugs for people.
Bayer and Evotec partner Haplogen will work to identify new treatments, such as antivirals, for pulmonary diseases.
A trio of aging-focused biotechs and research firms formed a joint venture to develop small molecules for a novel target hoping to extend life spans.
Acorda's chief technology officer Rick Batycky, Ph.D., is leaving the company next week after four years in the role to head up his own operation.
The setback threatens to wipe out Realm’s clinical-phase pipeline, leaving the immunology player with just a preclinical acne asset.
Sigilon Therapeutics is bringing on Bioverativ’s chief global therapeutic operations officer, Rogerio Vivaldi, M.D., to serve as its CEO.
A tool called “polygenic risk scoring” could help physicians identify who faces a high risk of serious diseases.